Benjamin Chen

Benjamin is a scientist, entrepreneur, investor, and merchant banker. He was most recently the CEO of
ImaginAb, Inc., a venture-backed company developing a cutting-edge platform to address an urgent
unmet need in immuno-oncology. Prior to that, he served as the Chairman and CEO of the London-based
Immune Targeting Systems, Ltd., leading the immune therapy company through significant strategic
growth, innovative product development, and establishing presences in France and North America. Before his return to operational roles, he spent nine years as a Managing Director at Burrill & Company, a global
life sciences venture firm where he evaluated investment opportunities and assisted a global clientele in
completing licensing, partnering and M&A transactions. He also played a key role in establishing the
Malaysian Life Sciences Fund I, and served as a director. Earlier in his career as an R&D executive, he had
experience in building talented research teams in immunology, stem cell biology, genomics, gene therapy,
and molecular diagnostics in both biotechnology start-ups and multinational pharmaceutical companies,
including Roche Diagnostics and Novartis. Ben received his academic training in Microbiology and Immunology at the University of Wisconsin-Madison and Stanford University.
Speaking In
1:00 PM - 2:00 PM (PDT)
Monday, June 13
Innovation and patients have brought us all closer than ever before despite an uncertain…